Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jin, Hye-Won | - |
dc.contributor.author | Kim, Hye-Rim | - |
dc.contributor.author | Eom, Yong-Bin | - |
dc.date.accessioned | 2022-09-06T06:41:57Z | - |
dc.date.available | 2022-09-06T06:41:57Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21373 | - |
dc.description.abstract | The aim of this study was to determine whether fingolimod could synergize the antibacterial activity of doripenem against carbapenem-resistant Escherichia coli (CREC) and its potential as an antibiotic adjuvant for doripenem. The E. coli used in this study had the bla(KPC) gene and became resistant to many classes of antibiotics, particularly carbapenems. The minimum inhibitory concentrations (MICs) of fingolimod and doripenem were determined. To investigate the synergistic action between fingolimod and doripenem, synergy checkerboard, growth curve, and time-kill analyses were performed. A motility test was also performed using a semi-solid medium to determine whether fingolimod could inhibit the motility of E. coli, one of its virulence mechanisms. The expression levels of carbapenemase-, motility-, and efflux pump-related genes suppressed by fingolimod were analyzed by quantitative polymerase chain reaction (qPCR). Our study demonstrated that the combination of fingolimod and doripenem inhibited carbapenemase, biological activity and other CREC virulence factors. This study findings suggest the potential of fingolimod as an adjuvant to prevent antibiotic resistance in CREC. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-Resistant Escherichia coli | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/antibiotics11081043 | - |
dc.identifier.scopusid | 2-s2.0-85137330612 | - |
dc.identifier.wosid | 000846396100001 | - |
dc.identifier.bibliographicCitation | Antibiotics, v.11, no.8, pp 1 - 10 | - |
dc.citation.title | Antibiotics | - |
dc.citation.volume | 11 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 10 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ENTEROBACTERIACEAE | - |
dc.subject.keywordPlus | EFFLUX | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | ACRD | - |
dc.subject.keywordPlus | PCR | - |
dc.subject.keywordAuthor | fingolimod | - |
dc.subject.keywordAuthor | doripenem | - |
dc.subject.keywordAuthor | carbapenem | - |
dc.subject.keywordAuthor | carbapenemase | - |
dc.subject.keywordAuthor | Escherichia coli | - |
dc.subject.keywordAuthor | synergistic action | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.